Jang Wonseok
Yonsei University · Medicine
About the Lab
Professor Jang Wonseok's research lab specializes in urological oncology, with a primary focus on prostate and renal cell carcinomas. The lab investigates peri-operative and oncological outcomes of minimally invasive surgical techniques such as robot-assisted radical prostatectomy, explores biomarkers like neutrophil-to-lymphocyte ratio for predicting disease recurrence, and examines the impact of pathological grading discrepancies between biopsy and surgical specimens. Additionally, the lab contributes to translational research in immunotherapy, particularly combining oncolytic viruses with immune checkpoint inhibitors for advanced renal cell carcinoma.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15OBJECTIVE: To investigate the peri-operative and oncological outcomes of robot-assisted radical prostatectomy (RARP) in patients with oligometastatic prostate cancer (PCa). PATIENTS AND METHODS: We retrospectively reviewed the records of 79 patients with oligometastatic PCa treated with RARP or androgen deprivation therapy (ADT) between 2005 and 2015 at our institution. Of these 79 patients, 38 were treated with RARP and 41 were treated with ADT without local therapy. Oligometastatic disease was
PURPOSE: In prostate cancer ductal adenocarcinoma is mixed with the usual acinar adenocarcinoma. However, to our knowledge whether the proportion of the ductal component affects oncologic outcomes is currently unknown. We investigated whether the proportion of the ductal component predicts oncologic outcomes in ductal adenocarcinoma. MATERIALS AND METHODS: We retrospectively reviewed clinical data on 3,038 patients with prostate cancer who underwent radical prostatectomy at our institution betwe
// Won Sik Jang 1 , Kang Su Cho 1 , Myung Soo Kim 1 , Cheol Yong Yoon 1 , Dong Hyuk Kang 1 , Yong Jin Kang 1 , Won Sik Jeong 1 , Won Sik Ham 1 , Young Deuk Choi 1 1 Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea Correspondence to: Young Deuk Choi, email: youngd74@yuhs.ac Won Sik Jang, email: sindakjang@yuhs.ac Keywords: neutrophil-to-lymphocyte ratio, prostate cancer, radical prostatectomy, biochemical recurrence, survival Received: Septe
PURPOSE: Percutaneous nephrolithotomy (PCNL) is conventionally conducted in the prone position. However, the prone position increases anesthesia-related morbidity and position changes lengthen the operation time. We report perioperative outcomes and the learning curve for flank PCNL on the basis of a single surgeon's experience. MATERIALS AND METHODS: This study investigated 53 cases of flank PCNL performed for renal stones at our institution from April 2008 to September 2010. We compared mean o
BACKGROUND: Recently, a new prostate cancer (PC) grading system was introduced, where Gleason score (GS) 7 was divided into 3 + 4 = 7 and 4 + 3 = 7 due to the different prognoses associated with each tumor type. However, whether downgrading or upgrading from needle biopsy (NB) to radical prostatectomy (RP) affects oncologic outcomes is currently unknown. Herein, we investigated the prognostic impact of downgrading and upgrading from NB to RP among men with GS 7 PC. METHODS: We retrospectively re
BACKGROUND: Although a combination of immune checkpoint inhibitors (ICIs) is recommended as the first line treatment option for metastatic renal cell carcinoma (mRCC), several immune-related adverse events (irAEs) occur, especially hepatitis. We explored the therapeutic benefits and safety profile of combining oncolytic vaccinia virus, JX-594, with a programmed cell death protein-1 (PD-1) inhibitor. METHODS: We used early-stage and advanced-stage orthotopic murine mRCC models developed by our gr
BACKGROUND: The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) remains unclear in the immuno-oncology (IO) era. The results of two randomized trials, CARMENA and SURTIME, questioned the role and timing of CN. However, despite the latest advances in the systemic treatment of mRCC, previous trials have only used targeted therapy, and no studies have fully investigated the role of CN in immune checkpoint inhibitor (CPI) settings, and there is an ur
SP-pyeloplasty showed cosmetic benefits, lower blood loss, operative time, and console time compared with MP-pyeloplasty. In patients who underwent surgery for UPJO for the first time, SP surgery can show comparable outcomes when compared to MP surgery.
Research Areas
Dive deeper into Jang Wonseok's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.